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Small non-coding RNA landscape of 
extracellular vesicles from human 
stem cells
Sippy Kaur1, Ahmed G. Abu-Shahba1,4, Riku O. Paananen3, Heidi Hongisto2, 
Hanna Hiidenmaa1, Heli Skottman2, Riitta Seppänen-Kaijansinkko1 & Bettina Mannerström  1
Extracellular vesicles (EVs) are reported to be involved in stem cell maintenance, self-renewal, and 
differentiation. Due to their bioactive cargoes influencing cell fate and function, interest in EVs in 
regenerative medicine has rapidly increased. EV-derived small non-coding RNA mimic the functions 
of the parent stem cells, regulating the maintenance and differentiation of stem cells, controlling the 
intercellular regulation of gene expression, and eventually affecting the cell fate. In this study, we used 
RNA sequencing to provide a comprehensive overview of the expression profiles of small non-coding 
transcripts carried by the EVs derived from human adipose tissue stromal/stem cells (AT-MSCs) and 
human pluripotent stem cells (hPSCs), both human embryonic stem cells (hESCs) and human induced 
pluripotent stem cells (hiPSC). Both hPSCs and AT-MSCs were characterized and their EVs were 
extracted using standard protocols. Small non-coding RNA sequencing from EVs showed that hPSCs 
and AT-MSCs showed distinct profiles, unique for each stem cell source. Interestingly, in hPSCs, most 
abundant miRNAs were from specific miRNA families regulating pluripotency, reprogramming and 
differentiation (miR-17-92, mir-200, miR-302/367, miR-371/373, CM19 microRNA cluster). For the AT-
MSCs, the highly expressed miRNAs were found to be regulating osteogenesis (let-7/98, miR-10/100, 
miR-125, miR-196, miR-199, miR-615-3p, mir-22-3p, mir-24-3p, mir-27a-3p, mir-193b-5p, mir-195-3p). 
Additionally, abundant small nuclear and nucleolar RNA were detected in hPSCs, whereas Y- and tRNA 
were found in AT-MSCs. Identification of EV-miRNA and non-coding RNA signatures released by these 
stem cells will provide clues towards understanding their role in intracellular communication, and well 
as their roles in maintaining the stem cell niche.
Stem cells are responsible for the development and regeneration of tissues and maintaining steady-state of organ 
homeostasis. Stem cells of various types exist; pluripotent stem cells (PSCs), such as embryonic stem cells (ESCs) 
and induced pluripotent stem cells (iPSCs) have the potential to differentiate into all types of adult human tissues, 
while stem cells residing in the adult individual, such as mesenchymal stem/stromal cell (MSCs) have a more 
limited differentiation capacity1. Tissue development and regeneration involves cell activities such as recruitment, 
proliferation and differentiation, which are mediated by autocrine or paracrine effectors2. Therapeutic activities 
mediated by paracrine signalling in stem cells have been well documented.
The paracrine effectors of stem cells, such as extracellular vesicles (EVs), which mimic stem cell properties, 
could represent a relevant therapeutic option in regenerative medicine. EVs are important mediators of inter-
cellular communication and regulate bidirectional transfer of proteins, lipids and nucleic acids between cells via 
specific receptor-mediated interactions3. The contribution of stem cell-derived EVs in lineage commitments, 
maintenance of self-renewal, differentiation, maturation, efficiency of cellular reprogramming and cell fate 
determination are largely regulated by non-coding RNA (ncRNA)4. Small ncRNA (<200 nucleotides) includes 
microRNA (miRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), piwi-interacting RNA 
(piRNA), transfer RNA (tRNA), small ribosomal RNA (rRNA), and small cytoplasmic RNA (Y RNA). These are 
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involved in various biological processes and maintain the equilibrium between pluripotency and differentiation 
in stem cells, thereby aiding in governing stem cell potency and lineage-specific fate decisions5,6. Furthermore, the 
ncRNAs are known to be sorted into EVs thus modulating cellular processes7,8. Therefore, EV-derived ncRNAs 
are potential mediators of paracrine effects of stem cells.
Small ncRNAs, particularly microRNAs (miRNAs) which are central to gene regulation and cellular fate deter-
mination, can also mediate their regulatory effects via EVs9. miRNAs are small endogenous non-coding RNAs 
that function as posttranscriptional regulators of gene expression through translational inhibition or by promot-
ing the degradation of mRNA. They are important regulators of reprogramming processes, maintenance of pluri-
potency and differentiation of stem cells10. EV-derived miRNAs thereby are mediators of the extended paracrine 
effects of stem cells11–13. Thus, it could be concluded that intercellular communication mediated by transfer of 
EV-derived miRNAs coordinate the intercellular regulation of gene expression, which eventually affects the fate 
of the stem cells and their surrounding niches.
The primary goal of this study was to characterize the EV-derived miRNAs and other small ncRNAs of 
AT-MSCs and hPSCs cultured in vitro, and to explore their biological relevance. Identification of EV-miRNA and 
other small ncRNA signatures released by these stem cells will provide clues towards understanding the role of 
these extracellular RNAs in intercellular communication and their role in regulation of stemness in vitro.
Taken together, our data indicates that the miRNAs previously reported to be the important regulators of 
stem cells at cellular level are also present in their EVs, indicating a regulatory role that can be mediated via EVs. 
Therefore, transfer of these miRNAs and small ncRNA to other cells may promote lineage commitment in stem 
cells, and subsequently enhance differentiation in a cell therapy setting.
Results
hPSCs and AT-MSCs showed characteristics typical of respective stem cell type. Both stem cell 
types (MSC and PSC) were characterized with standard methods for the respective cell type in conjunction with 
media collections for EV extraction. The cells showed characteristic morphology, marker expression, and differ-
entiation capacity.
Human PSCs grew as well-defined colonies (Fig. 1A) and further as smooth monolayers reaching confluence, 
typical to undifferentiated hPSCs on laminin-521. The cells showed uniform expression of core pluripotency tran-
scription factors Nanog, and octamer-binding transcription factor-3/4 (OCT-3/4), as well as typical hPSC surface 
marker expression of stage-specific embryonic antigens (SSEA) -3 and -4, tumor rejection antigens (TRA)-1-60 
and -1-81, as well as lack of expression of early differentiation marker SSEA-1 (Fig. 1B). Further, the cells showed 
normal diploid karyotypes (Fig. 1C). Pluripotency was confirmed in vitro as differentiation capacity to derivative 
cells of all three embryonic germ layers (Fig. 1D). Characterisation of the hPSC-1 line is shown in Fig. 1 and 
hPSC2 line in Supplemental 1.
The characterization of AT-MSCs conformed with previous results14,15 and the standards defined by the 
International Society for Cellular Therapy (ISCT)16, by cells being successfully isolated and expanded as adherent 
fibroblast-like cells. Further, the AT-MSCs cultured in FBS-supplemented medium expressed surface markers 
CD54, CD73, CD90 and CD105, while lacking the expression of hematopoietic markers CD14, CD19, CD45 
and HLA-DR (Fig. 2A). In addition, AT-MSCs showed moderate expression of CD34, as previously reported for 
AT-MSCs14,15,17. Furthermore, CD34 and CD54 showed donor variability18.
The osteogenic differentiation capacity was analyzed for the AT-MSC donor cell lines, assessing both early 
differentiation capacity by alkaline phosphatase activity and later phase by alizarin red staining for mineralized 
matrix formation. The early response showed that the osteogenic differentiation capacity gradually increased up 
to 21 days in osteogenic induction cultures (OM), while control conditions (MM) showed low or no response 
(Fig. 2B). The alkaline phosphatase activity was normalized to the total DNA. Similarly, the later phase response 
in terms of mineralized matrix formation, showed gradual increase of matrix accumulation up to 21 days in OM, 
with no matrix formation seen in control conditions (Fig. 2C,D).
hPSCs and AT-MSCs showed robust secretion of EVs with a cell type specific size distribu-
tion. EVs were extracted from the culture media of AT-MSCs and hPSCs using ultracentrifugation15. Both cell 
types secreted abundant amount of EVs and their presence was confirmed by NTA, EM and WB. Characterization 
of EVs by NTA (Fig. 3A,B) supported the WB analysis with EV markers such as TSG101, Hsp70, CD63, CD90 
(Fig. 3C). EM indicated the presence of heterogeneous population of EVs in both cell types (Fig. 3D,E). WB 
results indicated that AT-MSC EVs showed stronger signals of CD63 and CD90 than hPSC EVs. TSG101 expres-
sion was seen in both cell lines EVs. hPSC EVs showed a clear band of Hsp70, whereas due to technical rea-
sons Hsp70 signal was not detectable (N.D) in AT-MSC EVs. Differences in the expression level of EV markers 
between cell types in our study could be explained by fact that the EV biogenesis pathways could be different 
among these cell lines. The purity of EVs was confirmed with the absence of the endoplasmic reticulum marker 
calnexin in all our EV samples. NTA results showed that AT-MSCs contained 2–4 × 104 of the 100–200 nm sized 
particles as the major group with a distribution of other sizes in smaller quantities, while hPSCs secreted 1.8–
2.3 × 105 of 100–200 nm sized particles (101–200 nm) and very small quantities of larger particles. The media 
used for EV collections were analyzed parallel to samples. EV-depleted FBS used in AT-MSC culture media was 
analyzed by NTA displayed large number of particles (101–200 nm), hPSC medium on the other hand as expected 
contained insignificant amounts of EV sized particles. Particle size determination by NTA is not entirely accurate 
as it cannot differentiate EVs from other particles such as protein aggregates and lipoproteins19. This results in 
false positives and impairs the reliability of the analysis. Therefore a combination of TEM, which was also used in 
this study is needed to visualize and confirm the presence of vesicles.
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hPSCs and AT-MSCs EVs have unique miRNA signature. Next generation sequencing was used to 
determine the small ncRNA expression profile of five EV samples (3 × AT-MSC and 2 × hPSC) as well as the 
corresponding media. Mapping of the reads from the sequencing is shown in Fig. 4, 71% and 43% of the reads of 
hPSC and AT-MSC samples, respectively, failed to align to the reference genome or were discarded, since they 
were outmapped, ie. mapped to abundant sequences such as polyA and polyC homopolymers, ribosomal RNA, 
the mitochondrial chromosome or ΦX174-genome. Most outmapped reads (>80% in all samples) were mapped 
to 28 S, 18 S, or 5.8 S ribosomal RNA. Out of the remaining reads, approximately half were mapped to small RNAs. 
On average, 13% of small RNA reads in hPSC samples were mapped to miRNA, while tRNA fragments (69%), Y 
RNA (7%), snRNA (4%), snoRNA (7%) and piRNA (<1%) made up the rest of reads. In AT-MSC samples, only 
miRNA (44%), tRNA (47%) and Y RNA (8%) were detected, while other small RNA types comprised <1% or 
total reads.
Length distribution of reads is shown in Fig. 5. An average of 21.5 million and 8.5 million raw reads were 
obtained from hPSC and AT-MSC samples, respectively, whereas 7.2 million (hPSC) and 9.3 million (AT-MSC) 
Figure 1. PSC characterisation. (A) Human PSC-1 characterized for A) typical undifferentiated colony 
morphology in phase contrast image and (B) expression of pluripotency markers Nanog, OCT-3/4, SSEA-
3, SSEA-4, TRA-1-60, and TRA-1-81, and lack of expression of early differentiation marker SSEA-1 after 
immunofluorescence staining. Corresponding nuclei stains with DAPI shown. (C) Cells showed normal female 
(46, XX) karyotype after 28 passages in total (9 passages in feeder-free culture). The results of the KaryoLite 
BoBs assay are shown as signal relative to karyotypically normal female (/F, red) and male (/M, blue) genomic 
DNA used as a reference (equal to 1) for each of the probes covering both p and q arms of all chromosomes. 
Software threshold for changes shown as a green lines and deviations in red. (D) Pluripotency shown after 
spontaneous differentiation in vitro as expression of markers for mesoderm, endoderm, and ectoderm. All scale 
bars 200 µm.
www.nature.com/scientificreports/
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reads were obtained from the corresponding media. AT-MSC medium showed similar levels of mapped reads in 
the miRNA (20–25 nucleotides) and other small RNA (30–35 nucleotides) ranges as AT-MSC samples, except for 
sample AT-MSC-1, which had very high levels of miRNA reads. In contrast, hPSC medium had very low number 
of reads in the miRNA and smRNA range, resulting in a lower background signal in the hPSC samples compared 
to AT-MSC samples. The higher read count of hPSC samples compared to AT-MSC samples is explained by a 
large peak of 35–40 nucleotide reads, which were mostly mapped to ribosomal RNA.
Figure 2. AT-MSC characterisation. Surface marker expression (%) of undifferentiated AT-MSCs (n = 3) 
analyzed by flow cytometric analysis (A). Quantitative data of early and later phase response of osteogenesis 
by (B) alkaline phosphatase activity (early response) and (C) Alizarin red staining (late response). (D) Alizarin 
red staining for assessment of mineralized matrix formation. Results show no detection of mineralized matrix 
in control condition (MM), while osteogenically induced cultures (OM) show enhanced mineralized matrix 
formation after 21 days. Dots represent biological and technical replicates, and bars represent means. MM; 
maintenance medium, OM; osteogenic medium, ARS; alizarin red staining, ALP; alkaline phosphatase. Scale 
bar 100 μm.
www.nature.com/scientificreports/
5SCiEnTiFiC REPORTS |  (2018) 8:15503  | DOI:10.1038/s41598-018-33899-6
hPSCs and AT-MSCs have distinct miRNA and small RNA profiles. Unsupervised clustering was 
performed on EV-miRNAs in order to assess the variability among the samples (Fig. 6A). hPSC and AT-MSC 
samples showed clearly different EV-miRNA expression patterns, but strong similarity within sample groups was 
observed. Expression patterns of AT-MSC-1 was distinctively different from the other two replicates. This could 
be due to the medical history of this donor (gastric bypass, antidepressant medication). hPSCs showed a wider 
range of expressed EV-miRNAs compared to AT-MSCs, with 159 out of 463 miRNAs only present in hPSC EVs. 
Unsupervised clustering analysis on EV-derived small ncRNA also separated AT-MSCs from hPSCs (Fig. 6B). 
Figure 3. EV characterisation. (A,B) EV concentration and size distribution measured by nanoparticle tracking 
analysis (NTA). On y-axis concentrations (particles 106/ml) are shown and on x-axis EV samples of hPSC, AT-
MSC and their respective medias; hPSC media, and dAT-MSC media (EV-depleted AT-MSC media). In general. 
hPSCs contained more particles than AT-MSCs. (C) Western blotting showed presence of stronger signals of 
EV markers CD63 and CD90 in AT-MSC EVs as compared to hPSC EVs. TSG101 expression was seen in both 
hPSC and AT-MSC EVs. hPSC EVs showed clear band of hps70, whereas Hsp70 signal was not detectable (N.D) 
in AT-MSC EVs due to technical reasons. Absence of Calnexin protein in all the EV samples indicated purity of 
the samples. (D,E) TEM images of hPSC and AT-MSCs. Scale bar 500 nm.
Figure 4. Mapping of sequencing reads. Relative composition of diverse RNA classes in hPSC and AT-MSC 
EVs. Only 1.4-1.5% and 2.5–37% of total reads mapped to miRNA in hPSC and AT-MSC, respectively.
www.nature.com/scientificreports/
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Figure 5. Sequencing reads length distribution. Length distribution of aligned reads from all 5 EV stem cell 
samples and their respective media.
Figure 6. Heat map cluster analysis of EV-RNA. Unsupervised cluster analysis on AT-MSC and hPSC based 
on their EV-miRNAs (A) and ncRNAs (B). AT-MSCs and hPSCs clearly clustered separately based on both EV-
derived miRNA and ncRNA.
www.nature.com/scientificreports/
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SNORD family was exclusively present in hPSC-EVs, whereas Y and tRNA fragments were highly expressed in 
AT-MSCs EVs (Supplemental 2).
EV-miRNAs were divided into groups based on significant (p < 0.01) differential expression or expression in 
both sample types (|FC| < 2) and a cutoff of 32 mean counts per million (CPM) (Tables 1 and 2). AT-MSCs and 
hPSCs had unique miRNA profiles at their EV level. Finally, 32 EV-miRNA, majority of which are positive and 
negative regulators of osteogenic differentiation was exclusively present in MSC, whereas 77 miRNA involved 
in maintaining pluripotency (including mir families: mir-371/372, mir-302/367, 200, 17/92 and C19MC) were 
highly represented in hPSC.
Comparison of miRNA and other small RNAs detected in hPSC and AT-MSC medias. Due to 
the relatively high number of reads obtained from the AT-MSC medium, we compared each type of samples to 
their respective media. Various normalization strategies are used for EV-RNA data, such as library size, geomet-
ric mean, endogenous references, or external spike-ins20. Since practically no similarity in RNA content can be 
assumed to exist between the unconditioned media and cell-derived EV samples, we normalized the reads to 
external spike-ins, as has been done previously to compare RNAs between different types of samples8. As can be 
seen in Fig. 7, considerable amounts of both miRNAs and other small RNAs were identified in the media (for full 
list, see Supplemental 3). Especially in AT-MSC medium, levels of several RNAs were similar to AT-MSC samples. 
To take this into account, RNAs were required to have at least 2 times higher normalized read count compared to 
media in all samples to be included in unsupervised clustering and isomiR analysis (see Materials and Methods 
for details).
Family Family members log2FC log2CPM pValue FDR Major Functions in PSCs Reference
mir 17-92 hsa-miR-17-5p −4,34568 9,012717 0,000855 0,00184 Controls proliferation of embryonic stem cells
94
hsa-miR-18a-5p −4,12927 5,365265 0,002687 0,005021
hsa-miR-20a-5p −3,39956 9,942874 5,93E-05 0,000159
hsa-miR-92a-3p −2,28835 14,64776 0,005145 0,009065
mir-200 hsa-miR-200a-3p −4,18521 6,916635 0,005677 0,009636
regulates differentiation, 
Maintaining pluripotency 
and regulates epithelial-
mesenchcymal transition
95
hsa-miR-200a-5p −4,53501 5,812451 0,000615 0,001422
hsa-miR-200b-3p −6,81357 10,64906 1,04E-06 4,1E-06
hsa-miR-429 −9,26846 6,001451 4,62E-08 2,59E-07
mir-302/367 hsa-miR-302a-3p −15,6675 12,33651 9,32E-25 1,3E-22 Maintaining pluripotency 42
hsa-miR-302a-5p −13,4935 17,28532 5,1E-20 1,89E-18
hsa-miR-302b-3p −13,5506 16,09634 9,86E-18 3,04E-16
hsa-miR-302c-3p −15,5738 12,24285 1,41E-24 1,3E-22
hsa-miR-302c-5p −11,0944 9,555795 6,18E-16 1,27E-14
hsa-miR-302d-3p −13,7161 12,16085 4,98E-23 3,07E-21
hsa-miR-302d-5p −8,71179 5,475559 5,61E-07 2,36E-06
hsa-miR-367-3p −9,95691 6,665547 2,02E-09 1,29E-08
mir-371/373 hsa-miR-371a-3p −8,62254 5,393327 1E-06 4,03E-06 regulating cell proliferation, differentiation
35
hsa-miR-371a-5p −11,2134 7,898332 1,21E-12 1,32E-11 and reprogramming
hsa-miR-372-3p −13,3871 11,83298 3,78E-22 1,75E-20
hsa-miR-373-3p −9,00191 5,748367 1,49E-07 7,63E-07
C19MC hsa-miR-516a-5p −8,51958 5,296551 2,2E-06 7,52E-06 maintaining stem cell self-renewal and pluripotency
96
hsa-miR-516b-5p −9,69778 8,987653 1,64E-13 2,09E-12
hsa-miR-517a-3p −9,14288 5,88151 9,03E-08 4,78E-07
hsa-miR-517b-3p −8,77055 5,528605 1,4E-06 5,17E-06
hsa-miR-518b −10,5662 7,260425 5,46E-11 4,39E-10
hsa-miR-520c-3p −8,57565 5,348277 1,68E-06 5,87E-06
hsa-miR-520f-3p −10,0952 6,799461 1,09E-09 7,46E-09
hsa-miR-520g-3p −8,2576 6,709774 1,25E-08 7,47E-08
hsa-miR-522-3p −8,44063 5,225189 2,99E-06 1,01E-05
hsa-miR-523-3p −8,20928 5,013337 1,17E-05 3,49E-05
hsa-miR-526b-5p −8,8302 5,585032 7,1E-07 2,92E-06
hsa-miR-1323 −11,8527 8,531433 1,69E-13 2,09E-12
Table 1. Differentially expressed major EV-miRNA families in hPSC with the corresponding normalized 
counts and p-values.
www.nature.com/scientificreports/
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IsomiR identification. It is known that majority of miRNA genes encode isomiRs with 3′ or 5′ modifica-
tions. We restricted the isomiR identification to the major miRNA families in both stem cell types most abundant 
miRNAs present in both stem cell types (Tables 1 and 2). Our analysis showed that both hPSC and AT-MSC 
expressed isomiRs as shown in Fig. 8, where the frequency of different types of modifications in the identified 
miRNA families are highlighted. Some type of variation was present in a high proportion (72%) of the miRNA 
reads. In hPSC samples, majority (66%) of miRNAs were mostly comprised of the canonical isomiR and variation 
in the 3′ end was the most common isomiR type. In contrast, majority (53%) of AT-MSC miRNAs were mostly 
present as isomiRs with 3′ variation, and only 34% of miRNA were mostly present as the canonical isomiR. 
However, these common modifications are not as likely to have functional importance as the rarer variations in 
the 5′ end or in the miRNA seed region. Interestingly, some miRNAs in hPSC EVs (miR-302a-5p, miR-520f-3p, 
miR-523–3p) were predominantly present as isomiRs with 5′-end modifications.
Discussion
Understanding the exact composition of EV-derived small ncRNA of defined stem cell type will increase our 
knowledge about their role in intercellular communication as well as their potential as diagnostic biomarkers. 
Studies with in-depth characterization of EV-derived ncRNA from clinical grade hPSCs are lacking, and only 
few studies have explored EV-derived ncRNA of AT-MSCs. The present study utilized high-throughput RNA 
sequencing to provide an in-depth characterization of small ncRNAs in EVs derived from human AT-MSC and 
hPSC. This approach identified stem cell specific differences in ncRNA including: miRNA, miRNA isoforms, 
tRNA, yRNA, snoRNA, and snRNA. Limitation of the study is the low number of samples per group (n = 2–3), as 
Family Family members log2FC log2CPM pValue FDR Major Functions in MSCs References
let-7/mir-98 hsa-let-7a-3p 9,151431 6,477715 1,41E-05 4,15E-05 Regulates differentiation 53,54,64
hsa-let-7a-5p 4,438344 13,48553 5,38E-06 1,72E-05
hsa-let-7b-3p 9,306488 6,621799 5,87E-05 0,000159
hsa-let-7b-5p 9,666006 14,19212 5,27E-13 6,09E-12
hsa-let-7c-5p 6,377311 10,45171 5,57E-09 3,43E-08
hsa-let-7e-5p 5,912685 9,64524 2,31E-07 1,15E-06
hsa-let-7f-5p 6,292228 12,90261 1,65E-09 1,09E-08
hsa-let-7i-5p 8,040472 14,0149 9,88E-12 9,62E-11
hsa-miR-98-5p 10,92755 8,203416 1,92E-08 1,11E-07
mir-10/100 hsa-miR-10a-5p 7,995657 13,27917 2,67E-10 1,9E-09
hsa-miR-10b-3p 7,559436 5,017372 0,001355 0,002849
hsa-miR-10b-5p 8,498145 14,36205 8,18E-12 8,41E-11
hsa-miR-100-5p 4,009269 13,98291 0,000211 0,000519 negative regulator of osteogenic differentiation
62
mir-125 hsa-miR-125a-5p 3,250007 10,45281 0,000975 0,002073
hsa-miR-125b-1-3p 5,844325 8,026384 0,004338 0,007792 Suppress osteogenesis 63,97
hsa-miR-125b-5p 6,371527 9,723062 3,62E-07 1,67E-06
mir-196 hsa-miR-196a-5p 7,26496 7,494054 0,001717 0,003378 Promotes osteogenesis 60
hsa-miR-196b-5p 7,761247 5,191769 0,00082 0,001792
mir-199 hsa-miR-199a-3p 3,994405 8,941022 0,000276 0,000671 Involved in osteogenesis/chondogenesis
98
hsa-miR-199a-5p 5,906115 9,147113 3,88E-06 1,28E-05
hsa-miR-199b-3p 3,924898 8,599356 0,000403 0,000968
hsa-miR-199b-5p 3,021359 7,643468 0,003009 0,005567 positive role in osteoblast differentiation
56
mir-148/152 hsa-miR-152-3p 4,293438 9,473328 4,73E-05 0,000131
hsa-miR-22-3p 4,552346 10,88709 5,96E-06 1,84E-05 regulating balance in osteogenesis/Adipogenesis
58
hsa-miR-24-3p 2,867598 10,70777 0,001581 0,003249 inhibits osteogenesis 66
hsa-miR-27a-3p 2,971421 11,04311 0,001444 0,003001 inhibits osteogenesis 66,99
hsa-miR-143-3p 6,997134 13,46121 1,9E-11 1,64E-10
hsa-miR-144-3p 10,80517 8,085471 1,68E-06 5,87E-06
hsa-miR-193b-5p 4,056847 6,250916 0,002251 0,004294 Regulate chondrogenesis 100
hsa-miR-195-3p 3,357619 6,148953 0,004834 0,008599 negative regulator of osteogenesis
65
hsa-miR-542-3p 4,172502 5,528398 0,005462 0,009455
hsa-miR-615-3p 9,77289 10,03215 2,62E-05 7,36E-05 negative regulator of osteogenesis
67
Table 2. Differentially expressed major EV-miRNA families in AT-MSC with the corresponding normalized 
counts and p-values.
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is the case for most sequencing studies on EVs until now. To overcome this, we have reported the miRNAs with 
the highest expression levels and included seq data from fresh media as controls, to account for the background 
signal from the media. Some of the miRNA and other small ncRNA identified in our AT-MSC data are in the 
line with previously published reports, which not only confirm our findings but also indicates that signature EV 
RNAs are not affected by the donor variations. Our data validated the previously identified cellular genes at EV 
level, thus highlighting the regulatory potential of EV-ncRNAs and the potential stem cell specific EV biomarkers 
for future studies.
With all EV isolation methods, a mixed population of vesicles with varying yield is generally obtained. There 
is no consensus regarding the isolation methods as of date. Therefore, method of choice depends on the down-
stream applications. Initially, we selected miRCURY EV isolation kit for both EV characterization and EV isola-
tion for RNA sequencing. Despite the dispute about residual cellular RNA in several EV precipitation methods21, 
miRCURY precipitation kit has been reported having better performance. The isolated fraction exhibited specfic 
surface markers, size distribution of the particles and microRNAs characteristic for EVs22. Due to high back-
ground with miRCURY precipitation kit, technical problems were encountered at all EV characterization steps. 
Therefore, we performed EV characterization using ultracentrifugation (UC). In our experience, for EV char-
acterization, isolation of EVs using UC technically stands out as a better option than commercially available 
precipitation kits15,23. Our approach of using two different EV isolation methods may have yielded different and 
overlapping EV populations. This observation is supported by a recent study where five different EV isolation 
Figure 7. Comparison of sample miRNA and small RNA to the respective media. Read counts normalized to 
external spike-ins for 38 miRNAs and other small RNAs with highest counts in each medium (blue) and mean 
counts in corresponding samples (red). Error bars depict the range of reads (min-max). miRNA and small 
ncRNA identified in hPSC media (A,B) and AT-MSC media (C,D).
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methods (including UC and precipitation based methods) were compared for profiling miRNAs by sequencing. 
They concluded that each method captured distinctive but partially overlapping EV populations, along with var-
ying degrees of non-EV contamination24.
EV isolation and RNA sequencing was done according to the Exiqon’s workflow. miRCURY precipitation kit 
was used to purify EVs. Before precipitation, two centrifugation steps were done to remove cellular components 
and two supernatant removal steps to get as much of the un-precipitated material away before the next step of EVs 
lysis followed by RNA extraction. Despite these critical attempts to remove non-EV contaminants, we still cannot 
rule out the possibility that our data is not only based on EV associated RNA, but also RNA co-isolated from the 
non-vesicular compartment could be also involved.
Small ncRNA profiles of AT-MSCs and hPSCs were unique and highly distinct from each other, which was 
consistent with previous publications. At transcriptomic and proteomic level, embryonic stem cell and bone mar-
row stem cells derived EVs displayed different EV-RNA and proteomic profiles25. Stem cells and stem cell derived 
EVs have been reported to exhibit several similar features which affects the stem cell fates, for instance similar 
miRNA expression profiles between MSCs and MSC-EVs has been documented26. In our dataset, 1.4–1.5% of 
total reads mapped to miRNA in hPSCs and 2.5–4% of reads mapped to miRNA in AT-MSC-2 and AT-MSC-3. 
However, AT-MSC-1 displayed a different distribution of reads, with markedly greater proportion of miRNA 
reads (37%). A possible explanation for the discrepancy between AT-MSC-1 and other samples is the gastric 
bypass surgery and the anti-depression medication used by the donor of AT-MSC-1 sample.
A large fraction of identified EV-miRNAs in our data were also previously reported to be expressed at cellular 
level7,26. miRNAs shuttled by MSC-derived EVs were shown to be involved in the control of transcription, cell 
survival, multi-organ development, differentiation and immune system regulation27.
Figure 8. isomiR identification: Distributions of isomiR types in major miRNA families identified in hPSC and 
AT-MSC EVs.
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A low percentage of miRNA reads is typical to extracellular vesicle samples8,28–33. Although the number of 
miRNA reads per sample was relatively low, miRNA reads were of high quality and mostly close to full length 
(Supplemental 5), as well as showed robust expression in both sample types (Fig. 6).
Several studies have shown that miRNAs are involved in regulating the unique ESC cell cycle, and also the 
balance between pluripotency and differentiation of hESCs34–36. At cellular level, there are generally subtle dif-
ferences in the miRNA profiles between the two pluripotent cell types (hESCs and hiPSCs)37. Our data showed 
very similar EV-miRNA patterns for the two pluripotent cell types indicating that irrespective of the derivation 
source, hPSCs release their characteristic miRNA content. In previous studies, human PSCs have shown charac-
teristic miRNA profiles undetectable in adult organs such as miR-302, miR-372, mir-17-92, mir-200, and C19MC 
families38. Our EV-miRNA data showed that hPSC also secreted these aforementioned hPSC specific miRNA 
clusters (Table 1).
The mir-200 and mir-302 are two large miRNA families involved in maintaining pluripotency by regulating 
the core regulatory circuitry of pluripotency genes (Nanog, OCT4, SOX2, KLF4). miR-302-driven cellular repro-
gramming coordinates stem cell division by regulating targets in the cell cycle, particularly at the G1/S restriction 
point35,38–40. Moreover miR-302 and miR-372 cluster miRNAs promote human somatic cell reprogramming to 
iPSCs41,42. Furthermore, these miRNAs repress multiple target genes regulating various other cellular processes, 
including epithelial-mesenchymal transition (EMT), epigenetic regulation and vesicular transport.
The chromosome 19 miRNA cluster (C19MC) is one of the largest miRNA gene clusters in the human genome. 
Expression of mir-516a, b-5p, 517a, b-3p, 518b, 520c, f, g-3p, 522-3p, 523-3p, 526b-5p, 1323 from C19MC was 
detected in our analysis. This primate-specific miRNA cluster is restrictively expressed in pluripotent ESCs40,43,44 
and, later during embryonic and fetal development, only in the placenta but not in other adult organs and tis-
sues45. C19MC miRNAs represent the majority of miRNAs not only in the trophoblast but also in EVs derived 
from it. The target genes are strongly associated with developmental processes and various cancers. It is suggested 
that these miRNAs may play critical roles in regulating differentiation and growth during the early development 
and in maintaining the pluripotency of hESCs46.
ESC-EVs have shown to promote the survival and improve the expansion of hematopoietic progenitor cells47 
and to induce de-differentiation and alterations in gene expression on cultured retinal progenitor Müller cells48. 
EV-treated Müller cells showed up-regulation of genes and miRNAs associated with cellular proliferation and 
induction of pluripotency and down-regulation of genes important to differentiation and cell cycle arrest. These 
findings suggest that by transferring stem cell-specific molecules, EVs can induce the activation of endogenous, 
adult, quiescent progenitor cells, increasing their pluripotency and possibly their ability to repair damaged tis-
sues. Our data confirmed that PSC-specific miRNA previously identified on cellular level are also found in EVs. 
Furthermore, additional EV-specific miRNAs were also identified, but deciphering their role need further studies.
In order to establish a global miRNA expression profile of MSCs, the consensus miRNAs in MSCs detected 
by different methods and from various sources have been previously reported49. Among which mir-199a, 152, 
125a, b, 143,100 and let-7b, c, e, f, were also identified in our AT-MSCs derived EVs (Table 2). Altogether our 
results strengthen the hypothesis that signature MSC miRNA are also expressed in their EV cargoes. Nine out 
of the highly expressed EV-miRNAs in our AT-MSC samples (let-7a-5p, let-7b-5p, let-7i-5p, miR-125-5p, miR-
199a-3p, miR-199b-3p, miR-100-5p, miR-144-3p and miR-22-3p) have previously been also found to be pres-
ent in bone-marrow-derived MSC EVs50. This clearly highlights that independent of cell of origin, MSCs share 
certain characteristic miRNA-EVs which are involved in regulating differentiation. mir-10a-5p, mir-10b-5p, 
mir-22-3p, mir-143-3p, mir-100-5p, let-7a, f-5p identified in our data have also previously been listed as most 
abundant miRNA in AT-MSCs EVs12. These results indicate that expression of these miRNA is unaffected by 
donor variability.
There are substantial numbers of experimental data confirming that miRNAs have multiple roles in regulating 
bone remodeling51 as well as osteogenesis. miRNAs are known to regulate osteoblast differentiation positively 
by targeting negative regulators of osteogenesis or negatively by targeting osteogenic factors52. Recently it has 
been reported that MSCs secrete miRNA and other small RNAs via EVs12. Our data revealed that in AT-MSCs, 
EV-miRNAs that modulate osteogenic commitments of AT-MSC, for example; let-7a and c, mir-22, 199a, 196a, 
199b and negative regulators of osteogenic differentiation such as mir-27, 98, 100, 615, 125b and 195 were 
enriched exclusively in AT-MSCs as compared to hPSCs (Table 2). This indicates that these EV-miRNAs have the 
potential to modulate bone differentiation pathways of the target cell.
Specifically, let-7 family, which is classically involved in stem cell differentiation, is considered as a global 
regulator of differentiation53. let-7c is known to enhance osteogenesis and thus bone formation while repressing 
adipogenesis of human MSCs by targeting HMGA254. let-7a and mir-199b were detected in the EVs during oste-
ogenic differentiation of BM-MSCs55. miR-199b-5p displayed positive role in osteoblast differentiation as it was 
significantly up-regulated during the osteogenesis in human BM-MSCs. Its functions as a positive regulator of 
osteogenesis is likely due to its involvement in GSK-3β/β-catenin signaling pathway56. miR-199a has been shown 
to increase osteogenic differentiation in vitro and to enhance ectopic bone formation in vivo. Expression of this 
miRNA is controlled by a HIF1α and Twist1 cyclic pathway57. mir-22 has been reported to enhance osteogenic 
differentiation of AT-MSCs by repressing its target HDAC6 and also by acting as a crucial regulator of switch 
between adipogenic and osteogenic differentiation58. EV delivery significantly enhances bone formation in vivo 
and bone regeneration has been speculated to be regulated by EV-derived mir-196a59. This miRNA has been 
shown to inhibit proliferation and enhance the differentiation process by regulating HOXC860.
Negative regulators of osteogenic differentiation (miR-100-5p, miR-125b-1-3p, miR-98-5p, miR-195-3p, miR-
24-3p, miR-27a-3p, and miR-615-3p) were exclusively expressed in our AT-MSC samples as opposed to hPSC 
samples. Many of these miRNAs affect well-known BMP induced osteogenic differentiation61. In AT-MSCs over-
expression of miR-100 inhibited osteogenic differentiation of stem cells by targeting BMPR262. mir125b directly 
targeting BMPR1b was identified as negative regulator of osteogenic differentiation of human BM-MSC63. mir-98 
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in BM-MSCs regulated osteogenic differentiation by targeting BMP264. mir-195 not only acts as a negative reg-
ulator of osteogenesis in human BM-MSCs, but also as an inhibitor of stem cell proliferative capacity and as 
an anti-angiogenic by targeting VEGF65. mir-27, whose promoter is negatively regulated by RUNX2, function-
ally inhibits osteogenesis by downregulating SATB2, which is an important regulator of osteogenic differenti-
ation66. mir-615 negatively regulates the osteogenic differentiation by suppressing osteogenic regulators GDF5 
and FOXO167. Thus EV-miRNAs which are negative regulators of osteogenesis could be the potential targets for 
enhancing bone regeneration as they can by directly delivered as anti-mir oligonucleotides into bone injury sites. 
The approach of using EVs as vehicles to deliver miRNA mimics or anti-mirs is certainly a potential tool in future 
bone regeneration applications.
IsomiRs, which are functionally different from their canonical microRNA are most probably generated by var-
iation in processing by Drosha and/or Dicer and differ by variations of a few bases at 5′ and 3′ end of miRNA68,69. 
They affect the half-life of miRNA, their sub-cellular localization and also their target specification70–72. IsomiRs 
with variations at the 3′ end were the predominant isomiR category identified in our data in both stem cell types 
(Fig. 8), and the ratio of isomiR reads to canonical miRNA reads was similar to earlier studies33,73. Exact func-
tion of isomiRs with 3′ modifications are not clearly known but are suggested to be related to a disease state74. In 
hPSC for example, we found that miR-302a, an important miRNA for hESCs self-renewal, showed predominant 
expression of the isomiR species with 5′ –end variations over its canonical miRNA. mir-302a isomiRs with unique 
seed sequences have indicated specificity in their target selection and therefore likely to be significant regulators 
of cellular differentiation75. Importance of the isomiRs in different stem cell types with variations at 3′ and 5′ end 
were reported by Tan et al.69, indicating that isomiRs are active in vivo and thereby have functionally importance 
as they co-immunoprecipitate with Ago proteins and are active in in vitro luciferace and cleavage assays.
Apart from miRNAs, 16 snRNA and 67 snoRNAs were the most highly-expressed non-coding RNA in 
hPSC-EVs. These non-coding RNAs play important roles in mRNA biogenesis and maturation8,76 and are also 
known to be involved in human cancers77. ncRNAs such as y and tRNA fragments displayed selectivity for 
AT-MSC which was consistent with recent reports12. Recent studies have reported that Y RNA fragments may 
play role in histone mRNA processing and cell damage78,79 and DNA replication80. Fragments derived from tRNA 
play important roles in regulating many biological processes, such as reverse transcription and guidance of other 
RNAs81. Functions of these ncRNAs in stem cell biology needs to be further elucidated.
Fetal bovine serum (FBS) used in cell culture experiments contains bovine EVs which interferes with the EVs 
produced by the cells. In our previous work we have reported that FBS used in cell culture experiments contains 
abundant amounts of EVs15. Ultracentrifugation (100,000 g for 19 hours), the most commonly used protocol 
for removal of FBS derived EVs, does not completely remove the EVs15. The current study support our previous 
findings, confirming presence of FBS derived miRNAs and small ncRNA in the EV depleted media (Fig. 7). 
Specifically, mir-122-5p, mir-423-5p and mir-148a-3p were the abundant miRNAs present in the media. mir-122 
has also been previously reported to be highly enriched in FBS82. Other miRNA and small ncRNA present in EV 
depleted FBS are shown in the Supplemental 3. This issue should be taken into consideration when drawing final 
conclusions about cell culture results as the interference and the biological effects associated with FBS derived 
RNA is not clearly known. hPSC medium used for culturing hPSCs, as expected, showed insignificant amounts of 
miRNAs and ncRNAs, assumed to be derived from medium components.
Conclusion
Overall, in our small scale analysis, we found that both AT-MSCs and hPSCs secrete a selective pattern of small 
ncRNA in there cell-free secretome. Their transfer to the target cells could be a mechanism of action for maintain-
ing the stem cell specific characteristics, orchestrating gene expression, and to mediating communication between 
neighboring cells. Understanding of paracrine regulation of pluripotency and differentiation commitment of 
stem cells, could have implications on the improvement of stem cell cultures and differentiation protocols. Thus, 
in-depth understanding of EV-derived ncRNA regulatory mechanisms could provide strategies for developing 
engineered EVs with therapeutic RNA.
Material and Methods
Culture and characterization of stem cells. hPSC lines. Human ESC line hPSC-1 was derived from 
surplus, blastocyst stage human embryo as described previously83. Human iPSC line hPSC-2 was generated at 
Prof. Katriina Aalto-Setälä’s laboratory at University of Tampere from dermal fibroblasts (Table 3). For this study, 
hPSCs were cultured in xeno- and serum-free Essential 8™ Flex Medium (E8 flex, Thermo Fisher Scientific), 
supplemented with 50 U/ml Penicillin-Streptomycin (Gibco, Thermo Fisher Scientific) on Corning® CellBIND® 
-well plates coated with 0.55 µg/cm2 human recombinant laminin-521 (LN-521, Biolamina, Sweden). Single cell 
Cell line ID Sex/Karyotype Passage Source/Details BMI AGE
hPSC-1 46XX p28 + 9FF Blastocyst — —
hPSC-2 46XX p26 + 9FF Skin/Sendai — —
AT-MSC-1 XX P5 Thigh 23.6 53
AT-MSC-2 XX P4 Abdominal flanks 22.7 32
AT-MSC-3 XX P1 Thigh 31.2 50
Table 3. Details of the hPSC and AT-MSC cell lines used in this study.
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passaging with TrypLE™ Select Enzyme (Gibco, Thermo Fisher Scientific) was carried out twice a week using 
split ratio of 40 000-50 000 cells/cm2 as described by Hongisto et al.84.
hPSC characterization. Human PSCs were characterized as described previously84. Briefly, the hPSCs were 
monitored regularly microscopically, and characterized by immunofluorescence staining (IHC) for expression of 
pluripotency markers using the following primary antibodies; Nanog (1:200, R&D Systems, AF1997), OCT-3/4 
(1:200, R&D Systems, AF1759), SSEA-3 (1:300, Novus Biologicals NB100–1832), SSEA-4 (1:200, R&D Systems, 
MAB1435), TRA-1-60 (1:200, Millipore, MAB4360), TRA-1-81 (1:200, Santa Cruz Biotechnology SC-21706), and 
early marker for differentiation SSEA-1 (1:200, Santa Cruz Biotechnology, SC-21702). Alexa Fluor-conjugated 
(1:400, ThermoFisher Scientific A-11055, A-21042, A-10037), and FITC-conjugated (1:400, Novus Biologicals, 
NB7102) secondary antibodies were used. Nuclei were counterstained with 4′,6′diamidino-2-phenylidole (DAPI) 
(Vector Laboratories Inc., Burlingame, CA).
Pluripotency was verified with in vitro pluripotency assay by spontaneous differentiation as embryonic bodies84, 
followed by immunofluorescence analysis for alpha-smooth muscle actin (SMA, 1:400, R&D Systems, MAB1420) 
for mesoderm, alpha-fetoprotein (AFP, 1:200, R&D Systems MAB1369) for endoderm, and OTX2 (1:200, R&D 
Systems, AF1979) for ectoderm. Karyotyping was performed at Finnish Microarray and Sequencing Centre 
(FMSC), Turku Centre for Biotechnology with the KaryoLite BoBs assay (Perkin Elmer).
AT-MSC lines. Human AT-MSC were obtained from water jet-assisted liposuction aspirates85 from three 
donors using mechanical and enzymatic isolation as described previously86. All donors were female, age range of 
32–53 (average 45) and BMI range of 22.7–31.2 (average 25.8) (Table 3). Cells were cultured in AT-MSC media 
consisting of Dulbecco’s modified Eagle’s medium/Ham’s Nutrient Mixture F-12 with 1% L-alanyl-L-glutamine 
(DMEM/F-12 1:1 GlutaMAX; Gibco ref. 31331–028, lot. 1765999), 1% antibiotics (100 U/ml penicillin, 0.1 mg/
ml streptomycin; Lonza ref. DE 17–602 E, lot. 5MB 068) and 10% FBS (Fetal Bovine Serum, South American ref. 
10270106, lot. 42F8554K) at 37 °C and 5% CO215. Once AT-MSCs had adhered to the culture flask, non-adherent 
populations were gently washed away with PBS and fresh culture media was added.
AT-MSC characterization. Cells cultured in AT-MSC media (n = 3) were characterized using BD Accuri C6 
flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) to confirm the mesenchymal origin of the cells. 
Allophycocyanin (APC)-conjugated monoclonal antibodies against CD14 (clone: M5E2), CD19 (clone: HIB19), 
CD34 (clone: 581), CD45RO (clone: UCHL1), CD54 (clone: HA58), CD73 (clone: AD2), CD90 (clone: 5E10), 
CD105 (clone: 266) and HLA-DR (clone: G46-6) (BD Pharmingen, Becton Dickinson) were used. Analysis was 
performed on 100.000 cells per sample, and the positive expression was defined as the level of fluorescence greater 
than 99% of the corresponding unstained cell sample15. Flow cytometric data is shown as average with standard 
deviation. Cells from three donors were plated at 2.000 cells/cm2 in four replicates per condition in 24-multiwell 
plate to analyse the osteogenic potential of AT-MSCs. Cells were first plated in AT-MSC media. After 24 h, oste-
ogenic differentiation was induced using osteogenic media (OM; AT-MSC media supplemented with 50 µM 
L-ascorbic acid 2-phosphate, 10 mM β-glycerophosphate disodium salt hydrate and 5 nM dexamethasone (all 
Sigma-Aldrich). At 7, 14 and 21days time points, osteogenesis was assessed using quantitative alkaline phos-
phatase activity (qALP) analysis which was normalized with total DNA quantification and quantitative Alizarin 
red staining (qARS) as reported previously15,87.
EV isolation and basic characterization. hPSC media collection for EV extraction was performed from 
four consecutive passages for both cell lines. Media were collected from 80–100% confluent cells cultures. The 
day after passaging, the hPSCs were rinsed twice with DPBS (Lonza), and fresh hPSC medium was added to the 
cells. 48 hours later, the hPSC conditioned media were collected to 50 ml Falcon tube, and immediately centri-
fuged 2,000 × g for 10 minutes at 4 °C to remove cell debris. Supernatant was transferred to a new Falcon tube 
and frozen to -80 °C for storage. Non-conditioned hPSC medium was collected as control. Prior to EV isolation, 
AT-MSCs were grown in EV-depleted medium for 72 hours. EV-depletion was performed as described previ-
ously15. Briefly, EV depleted FBS (dFBS) was prepared by 19 h ultracentrifugation of regular FBS at 26 000 rpm 
(121 896 gmax) using an SW28 rotor (k-factor 284.7, Beckmann-Coulter). Only the light coloured top layers of 
the supernatant (approx. 9/10) were retained and used in the subsequent analyses. The dFBS was filtered with a 
0.22 μm filter (Millipore Stericup-GP, 0.22 μm, polyethersulfone filter) before addition to cell-culture medium. 
For characterization, EVs were isolated from conditioned culture medium using ultracentrifugation as described 
previously15. Briefly, the conditioned medium was depleted of cell debris by centrifuging for 10 min at 2,500 x 
g and only the AT-MSC supernatant was filtered through a 0.45 μm sterile filter (Merck Millipore). EVs were 
extracted using ultracentrifuge at 26,000 rpm (121 896 gmax) for 2 hours at 4 °C with SW28 rotor to collect the 
EV pellet, which was washed by filtered PBS and stored in Protein LoBind microcentrifuge tubes (Eppendorf) at 
−80 °C. For RNA sequencing, EVs were isolated from the conditioned medium by precipitation using the miR-
CURYTM Exosome Isolation Kit (Exiqon A/S, Vedbaek, Denmark) according to the manufacturer’s instructions.
Nanoparticle tracking analysis (NTA). The number and size distribution of particles from isolated 
EV samples were analysed using Nanosight model LM14 (NanoSight Technology, Salisbury, U.K., http://www.
malvern.com) equipped with blue (404 nm, 70 mW) laser and CMOS camera (Hamamatsu Photonics K.K., 
Hamamatsu City, Japan). For the analyses samples were diluted in filtered (0.1 µm) DPBS to obtain the optimal 
detection concentration of 106–109 particles/ml, and triplicate 60 s videos were recorded using camera level 13. 
The data was analysed using NTA software 3.0 with the detection threshold 588.
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Transmission electron microscopy. Particle morphology was examined using transmission electron 
microscopy (TEM) Tecnai 12 (FEI Company, Eindhoven, the Netherlands) operating at 80 kV as described previ-
ously89. Briefly, after loading to 200 mesh copper grids and fixation with 2% PFA in 0.1 M NaPO4 buffer (pH 7.0), 
samples were washed with the 0.1 M NaPO4 buffer and deionized water, negatively stained with 2% neutral uranyl 
acetate and embedded in methyl cellulose uranyl acetate mixture (1.8/0.4%). Images were taken with Gatan Orius 
SC 1000B CCD-camera (Gatan Inc., USA) with 4008 × 2672 px image size and no binning. Samples from 2–3 
biological replicates were viewed.
Western blotting. Western blotting was performed as described previously89 using primary antibodies 
against Hsp70 (#554243, BD Biosciences), and CD63 (#556019, BD Biosciences) at 1:1000 dilution, as well as 
TSG101 (#SAB2702167, Sigma-Aldrich), and CD90 (#WH0007070M1, Sigma-Aldrich) at 1:500 dilution. The 
lack of calnexin served as an indicator for the purity of EVs samples, calnexin is an endoplasmic reticulum pro-
tein; probing of such protein involved the use of Calnexin (C5C9) Rabbit mAb (#2679, Cell Signaling Technology) 
at 1:800 dilution. EVs isolated by ultracentrifugation from equal volumes (20 mL) of each sample were loaded to 
gels. As controls, 30 µg of protein from AT-MSC and hPSC lysates measured by BCA assay (Pierce BCA Protein 
Assay Kit) were used, growth media for both AT-MSC and hPSC served as negative control samples. Probing for 
CD63 and CD90 was done on individual samples, however, due to limited amount of EV samples, Hsp70 and 
TSG101 protein detection was detected from pooled samples. Samples were denatured at 95 °C for 5 min in reduc-
ing Laemmli sample buffer; except for CD63 detection which was run in non-reducing conditions, separated 
using Mini-PROTEAN® TGX™ 12% gradient SDS-PAGE gel (Bio-Rad, Hercules, CA, USA) with prestained 
protein ladder (BlueSTAR Prestained Protein Marker, # MWP03, Nippon Genetics Europe GmbH) as a standard, 
running conditions were 150 V for 60 minutes. Blotting involved semi-dry transfer of proteins on nitrocellulose 
membranes, 0.2 µm (#162–0112, BIORAD), using 40 mA per gel for 60 minutes. Blocking and antibody incu-
bations were performed in Odyssey blocking buffer (LI-COR) with and without 0.1% Tween-20. After primary 
antibody overnight incubation at +4 °C, membranes were washed 4 × 5 minutes in TBS-T, and probed with sec-
ondary IRDye® 800CW Goat (Li-COR) at 1: 15,000 for 1 hour at RT. After incubation, membranes were washed 
4 × 5 minutes in TBS-T at RT and briefly rinsed with PBS 1×, then imaged on an Odyssey FC Imager (Li-COR). 
All original WB images are shown in Supplemental 4.
Small RNA sequencing. Sequencing experiments for three AT-MSC samples and two hPSC samples and 
the corresponding pure media were conducted at Exiqon Services, Denmark. EVs were isolated from 3 ml con-
ditioned cell culture media using miRCURY™ Exosome Isolation kit (Exiqon A/S). Before precipitation, two 
centrifugation steps were used to remove cellular components and two supernantant removal steps to get rid of 
the un-precipitated material, followed by EV lysis and RNA isolation using miRCURY™ RNA Isolation Kits - Cell 
& Plant (Exiqon A/S). Good performance of Exiqons EV isolation kit has been reported22. NGS libraries were 
prepared using the NEBNext® Small RNA Library preparation kit (New England Biolabs), consisting of adapter 
ligation, cDNA conversion, PCR amplification (18 cycles) and purification. From a total of 50 µl isolated RNA, 
6 μl was converted into microRNA NGS libraries. Library preparation QC was performed using Bioanalyzer 
2100 (Agilent). Based on the quality of the inserts and the concentration measurements the libraries were pooled 
in equimolar ratios. The pool was then size selected using the LabChip XT (PerkinElmer) aiming to select the 
fraction with the size corresponding to microRNA libraries (~145 nt). The library pools were quantified using 
the qPCR KAPA Library Quantification Kit (KAPA Biosystems). Single-ended sequencing with 50 cycles was 
then performed on the library pools using a NextSeq500 sequencing instrument according to the manufacturer 
instructions. Raw data was de-multiplexed and FASTQ files for each sample were generated using the bcl2fastq 
software (Illumina inc.).
Reads were mapped using Bowtie 2 software90 according to the Exiqon NGS Service microRNA/small-
RNA pipeline. First, reads mapped to spike-ins or outmapped (mapped to adapter sequences, ribosomal RNA, 
ΦX174-genome, mitochondrial RNA, or polyA and polyC homopolymers) with the following parameters: ‘-N 
0 -L 32–no-1mm-upfront -R 10 -D 15–n-ceil C,0–score-min C,0’, were discarded. Second, reads were mapped to 
mature miRNAs from miRBase 20 with the same parameters. Third, unaligned reads were mapped to GRCh37 
genome with the parameters ‘-N 1 -L 32 -R 4 -D 20–n-ceil L,0,0.15–rdg 200,51–rfg 200,51–score-min C,-250’. The 
reads were then quantified (including isomiR quantification) using custom Ruby scripts. IsomiRs were defined as 
sequences with a single base substitution or having 5′ and 3′ insertion/deletion compared to the mature canonical 
miRNA sequence.
Only RNAs with more than 1 CPM in at least two samples were included in the analysis. Unsupervised clus-
tering was performed using Euclidean distance metric and average linkage. Differential expression was calculated 
using the exact test for negative-binomially distributed counts with tagwise dispersion in the edgeR package 
3.20.191. For a large proportion of the identified miRNAs and smRNAs, similar quantities were also detected in 
the corresponding unconditioned media, especially for AT-MSC derived EVs (Fig. 8C,D), but also for hPSC EVs 
(Fig. 8A,B). Therefore, to filter out the RNAs possibly originating from the media, the following procedure was 
employed: first, raw read counts were normalized to external spike-ins (UniSp100-UniSp151), since assuming 
same levels of RNA for unconditioned media and EV samples is not appropriate. Second, RNAs overexpressed in 
either sample group (|Fold change| > 2) were required to have at least 2-fold higher spike-in normalized counts 
in all samples than in the corresponding media to be included in the analyses. RNAs with similar expression lev-
els between samples (|Fold change| < 2) were required to have at least 2-fold normalized counts in both sample 
groups. Multiple hypothesis correction was performed using the Benjamini-Hochberg procedure92 with a FDR 
limit of 0.01.
We have submitted all relevant data of our EV characterization to the EV-TRACK knowledgebase (EV-TRACK 
ID: EV180022)93.
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Ethical approval and informed consent. For the hPSCs, the research groups at the University of Tampere have 
approval of the National Authority for Medicolegal Affairs Finland (Dnro 1426/32/300/05) to use human embryos 
for research purposes, and supportive statements of the Ethical Committee of the Pirkanmaa Hospital District to 
derive, culture, and differentiate hESC lines (Skottman/R05116) and to use hiPSC lines in ophthalmic research 
(Skottman/R14023). No new hPSC lines were derived for this study.
For the AT-MSCs, the study was carried out with supportive statements of the ethical committee of Helsinki 
and Uusimaa Hospital District for the use of adipose tissue and derivatives (DNro 217/13/03/02/2015) and with 
informed consent from the donors. All methods were carried out in accordance with the relevant guidelines and 
regulations.
Data Availability
The RNA sequencing data has been deposited to the GEO (accession number GSE113868). We have submitted all 
relevant data of our EV characterization to the EV-TRACK knowledgebase (EV-TRACK ID: EV180022).
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